PPI’s and their risks, in perspective, from the ACG President.

The biggest admitted downside of PPI therapy at their introduction was cost. With the advent of over-the-counter and generic PPI’s, cost took a back seat and many more patients were managed on chronic, long-term PPI’s with no real attempt to stop or decrease that therapy. Over the past several years, a number of potential adverse